Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy in multiple myeloma: when, where, and for who?
Verkleij CPM, Korst CLBM, van de Donk NWCJ. Verkleij CPM, et al. Among authors: korst clbm. Curr Opin Oncol. 2020 Nov;32(6):664-671. doi: 10.1097/CCO.0000000000000677. Curr Opin Oncol. 2020. PMID: 32852308 Review.
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.
de Jonge AV, Duetz C, Bruins WSC, Korst CLBM, Rentenaar R, Cosovic M, Eken M, Twickler I, Nijland M, van der Poel MWM, de Heer K, Klerk CPW, Strobbe L, Oosterveld M, Boersma R, Koene HR, Roemer MGM, van Werkhoven E, Chamuleau MED, Mutis T. de Jonge AV, et al. Among authors: korst clbm. Blood Adv. 2024 Mar 12;8(5):1094-1104. doi: 10.1182/bloodadvances.2023011687. Blood Adv. 2024. PMID: 38191686 Free PMC article.
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement.
Heerma van Voss MR, Molenaar RJ, Korst CLBM, Bartelink IH, Baglio SR, Kruyswijk S, de Ruijter M, Zweegman S, Kuipers MT, van de Donk NWCJ. Heerma van Voss MR, et al. Among authors: korst clbm. Expert Opin Biol Ther. 2024 Sep;24(9):889-901. doi: 10.1080/14712598.2024.2397436. Epub 2024 Sep 1. Expert Opin Biol Ther. 2024. PMID: 39185748 Review.
Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T-cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.
De Jonge AV, Bruins WSC, Duetz C, Korst CLBM, Rentenaar R, Cosovic M, Eken M, Kersten MJ, Sandberg Y, Van Rijn RS, Fijnheer R, Mutsaers P, Vergote VKJ, Issa D, Beeker A, Bilgin YM, Visser O, Van Werkhoven E, Roemer MGM, Chamuleau MED, Mutis T. De Jonge AV, et al. Among authors: korst clbm. Haematologica. 2024 Jul 4. doi: 10.3324/haematol.2024.285170. Online ahead of print. Haematologica. 2024. PMID: 38961740 Free article.
Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing.
Korst CLBM, Groen K, Bosman PWC, van der Valk F, Verkleij CPM, Kruyswijk S, de Ruijter MEM, Heijink DM, Kuipers MT, Zweegman S, van de Donk NWCJ. Korst CLBM, et al. Hemasphere. 2024 Jul 24;8(7):e132. doi: 10.1002/hem3.132. eCollection 2024 Jul. Hemasphere. 2024. PMID: 39050549 Free PMC article. No abstract available.